Prescient Therapeutics extends share purchase plan to September 18
Published: 10:33 15 Sep 2026 AEST
Prescient Therapeutics Ltd (ASX:PTX) has extended the closing date of its share purchase plan (SPP) by three days to give eligible shareholders more time to participate following delays in receiving offer documentation.
The SPP will now close at 5.00pm AEST on Friday, September 18, rather than September 15.
Prescient noted that shareholder participation had been encouraging to date, with all eligible directors taking part in the offer.
Shares offered at 18.8% discount
New shares under the SPP are priced at A$0.065 each, representing an 18.8% discount to the volume-weighted average price over the 10 trading days before the offer was announced.
Eligible shareholders registered at 7.00pm AEST on August 24 can apply for up to A$30,000 worth of new shares.
Following the revised timetable, Prescient expects to announce the SPP results on September 24 and issue the new shares on September 25, with trading expected to begin on September 28, subject to ASX listing rules.
Applications can be made by BPAY or through the personalised application form, with payment required by the revised September 18 deadline.
Investor briefing on PTX-100
Chief executive James McDonnell will also host an online investor briefing on September 18 to discuss the company’s Dose Optimisation Committee review milestone and its implications for advancing lead drug candidate PTX-100 into its next stage of development.
PTX-100 is a first-in-class compound designed to block the cancer-related enzyme geranylgeranyl transferase-1, disrupting signalling pathways involved in tumour growth.
The drug has completed a Phase 1b expansion cohort study in T-cell lymphomas and is now being evaluated in a Phase 2 study in cutaneous T-cell lymphoma, with up to 40 patients expected to be enrolled in the Phase 2a component.
Prescient is also developing its OmniCAR and CellPryme cell therapy platforms, aimed at improving the targeting, persistence and effectiveness of cellular cancer therapies.